Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study
PurposeCD19 Chimeric Antigen Receptor T-cell therapy (CART) represents a groundbreaking approach in the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). However, a subset of patients fails to achieve optimal outcomes with …